Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com
European Commission Recommends Trastuzumab Deruxtecan Approval for Pretreated HER2+ Gastric Cancer
November 14th 2022The European Medicines Agency’s CHMP has recommended the approval of trastuzumab deruxtecan as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.
Read More
Regorafenib Plus Ipilimumab and Nivolumab Shows Intriguing Activity in MSS mCRC
November 8th 2022Regorafenib plus ipilimumab and nivolumab led to encouraging survival and responses in approximately half of patients with microsatellite stable, non–liver metastatic colorectal cancer who progressed on prior chemotherapy.
Read More
Iomab-B Conditioning Elicits Durable CR in Relapsed/Refractory AML
October 31st 2022Reduced-intensity conditioning treatment plus Iomab-B prior to bone marrow transplant led to a durable and statistically significant 6-month complete remission rate vs conventional care in older patients with active, relapsed/refractory acute myeloid leukemia.
Read More
Camizestrant Improves PFS Vs Fulvestrant in Advanced ER+ Breast Cancer
October 26th 2022Camizestrant led to a statistically significant improvement in progression-free survival compared with fulvestrant in postmenopausal patients with estrogen receptor–positive, locally advanced, or metastatic breast cancer who were previously treated with endocrine therapy for advanced disease.
Read More
Sintilimab Plus Chemotherapy Improves PFS in Pretreated, EGFR-Mutant NSCLC
October 25th 2022Sintilimab plus pemetrexed and cisplatin significantly improved progression-free survival vs pemetrexed and cisplatin alone in patients with advanced, EGFR-mutant non–small cell lung cancer who progressed on prior EGFR TKI therapy.
Read More
Xevinapant Plus Chemoradiotherapy Improves OS in Locally Advanced Head and Neck Cancer
October 22nd 2022Xevinapant plus chemoradiotherapy more than halved the risk of death vs placebo plus chemoradiotherapy without increasing toxicity in patients with unresectable, locally advanced head and neck squamous cell carcinoma.
Read More
European Commission Approves Second-line Axi-cel for DLBCL/HGBL
October 18th 2022The European Commission has approved axicabtagene ciloleucel for the treatment of adult patients with diffuse large B-cell lymphoma or high-grade B-cell lymphoma who relapse within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
Read More
EMA Endorses Cemiplimab Approval in Advanced Cervical Cancer
October 14th 2022The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for cemiplimab monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after platinum-based chemotherapy.
Read More
Long-Term Treatment With Ibrutinib Is Possible in Newly Diagnosed CLL/SLL
October 13th 2022Treatment with ibrutinib for at least 5 years showed favorable complete response rates and tolerability in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were randomized to receive the BTK inhibitor in the phase 3 RESONATE-2 trial.
Read More
Ibrutinib Plus Venetoclax Improves Undetectable MRD Responses in Elderly, Unfit CLL
October 13th 2022Fixed-duration treatment with ibrutinib and venetoclax led to deeper and prolonged undetectable minimal residual disease responses vs chlorambucil and obinutuzumab in the frontline treatment of elderly or unfit patients with chronic lymphocytic leukemia, translating to fewer relapses in the first year following treatment cessation.
Read More
Avelumab and Axitinib Elicits Responses in Advanced Thymoma and Thymic Carcinoma
October 12th 2022The combination of avelumab and axitinib demonstrated promising response rates and progression-free survival and an expected safety profile in pretreated patients with advanced type B3 thymoma and thymic carcinoma, according to findings from an ongoing phase 2 study.
Read More
Frontline BR Plus ASCT and Maintenance Rituximab Demonstrates Activity in Transplant-Eligible MCL
October 10th 2022Bendamustine plus rituximab followed by autologous stem cell transplant and maintenance rituximab led to comparable outcomes defined by progression-free survival and objective response rate compared with R-CHOP/R-DHAP and ASCT as induction therapy in patients with mantle cell lymphoma.
Read More
Tivozanib Improves OS in Long-Term Responders in Relapsed/Refractory, Advanced RCC
October 10th 2022Tivozanib demonstrated an improvement in overall survival compared with sorafenib in pretreated patients with advanced clear cell renal cell carcinoma, particularly in those who remained progression-free at 1 year and beyond.
Read More
Negative Trials Fail to Dampen Enthusiasm for Adjuvant, Combination Therapy in RCC
October 10th 2022Toni K. Choueiri, MD, provides perspective on key research in renal cell carcinoma, including the first demonstration of benefit with triplet therapy in metastatic clear cell disease, the expansion of HIF-2α inhibition into the first line, and success with VEGF/immune-oncology approaches in the non–clear cell population.
Read More
Dostarlimab Plus Chemotherapy Meets ORR End Point in Metastatic Nonsquamous NSCLC
October 5th 2022The addition of dostarlimab to chemotherapy led to an improvement in objective response rate vs pembrolizumab plus chemotherapy in patients with newly diagnosed metastatic nonsquamous non–small cell lung cancer.
Read More
SCO-101 Plus FOLFIRI Will Continue to Be Studied Despite Missing Primary End Point in mCRC
October 4th 2022The addition of SCO-101 to FOLFIRI chemotherapy was safe and tolerable but failed to elicit a greater than 30% reduction in tumor volume in patients with metastatic colorectal cancer, though study of the combination will continue.
Read More
Pacritinib Improves Transfusion Independence, Anemia Through ACVR1 Inhibition in Myelofibrosis
October 3rd 2022Treatment with pacritinib led to an improvement in transfusion independence and hemoglobin in patients with myelofibrosis according to findings from a retrospective analysis of the phase 3 PERSIST-2 trial.
Read More
GB2064 Reduces the Level of Bone Marrow Fibrosis in Myelofibrosis
September 30th 2022Treatment with GB2064 monotherapy for at least 6 months led to a reduction in collagen fibrosis of the bone marrow of at least 1 grade in 4 of 5 evaluable patients with myelofibrosis, according to topline findings from a planned intermediate assessment of the phase 2a MYLOX-1 trial.
Read More
FDA Accepts NDA for 18F-rhPSMA-7.3 as Diagnostic Imaging Tool in Prostate Cancer
September 29th 2022The FDA has accepted for review a new drug application for 18F-rhPSMA-7.3, an investigational radiohybrid PSMA-targeted PET imaging agent for diagnostic imaging of prostate cancer, according to an announcement from Blue Earth Diagnostics.
Read More